Metropolis Healthcare Limited , India's second-largest diagnostic chain, has reported a robust 23% year-on-year revenue growth to ₹429.00 crore for the quarter ended September 30, 2025 (Q2 FY26). The company's EBITDA grew by 19% to ₹109.00 crore, while profit after tax (PAT) increased by 13% to ₹53.00 crore compared to the same quarter last year.

Key Financial Highlights

Business Segment Performance

The company's growth was driven by strong performance across its business segments:

• B2C Revenue: ₹240.00 crore (+16% YoY)
• B2B Revenue: ₹189.00 crore (+33% YoY)
• TruHealth (wellness) Revenue: +24% YoY
• Specialty Testing Revenue: +33% YoY

Geographical Expansion and Acquisitions

Metropolis Healthcare has been actively expanding its presence across India:

• Revenue contribution from North India increased to 19% (from 17% in Q1 FY26)
• Tier III cities registered 13% revenue growth

The company's recent acquisitions have started showing positive results:

• Core Diagnostics achieved positive PAT and high single-digit EBITDA margins within two quarters of acquisition
• DAPIC (Dehradun) and Scientific Pathology (Agra) continue to outperform the company's average margin levels

Strategic Initiatives

Metropolis Healthcare is focusing on several key areas to drive growth:

1. Expanding its test menu, with a focus on high-value specialty and preventive health tests
2. Strengthening its presence in Tier II and Tier III markets
3. Enhancing digital capabilities to improve customer experience and operational efficiency
4. Pursuing strategic acquisitions to enter new geographies and expand service offerings

Management Commentary

Ameera Shah, Promoter and Executive Chairperson of Metropolis Healthcare, stated, "We've demonstrated that consistent growth and quality can go hand in hand. The swift turnaround of Core Diagnostics and the strong performance of our recent acquisitions in Dehradun and Agra reaffirm the strength of our integration strategy and our ability to create sustainable value through local excellence."

Surendran Chemmenkotil, Managing Director, added, "We delivered consistent results this quarter, in line with our guidance, even as lower incidence of vector-borne diseases impacted seasonal demand. Our focus on execution excellence, productivity enhancement, and operational optimization helped sustain growth momentum and deliver year-on-year margin expansion in H1."

Dividend Declaration

The Board of Directors has approved an interim dividend of ₹4.00 per equity share (face value of ₹2.00 each) for the financial year 2025-26.

Outlook

Metropolis Healthcare remains confident in achieving its stated growth and profitability targets for the rest of the year. The company continues to focus on deepening its presence across 750+ towns, with sharper penetration in Tier 2 and Tier 3 markets, supported by a strong product portfolio and productivity-enhancing initiatives in the network.

As Metropolis Healthcare continues to expand its footprint and enhance its service offerings, it is well-positioned to capitalize on the growing demand for quality diagnostic services in India.

Metropolis Healthcare , a leading diagnostic services provider, has reported a robust financial performance for the second quarter of the fiscal year 2025-26, with significant growth in both revenue and profitability.

Financial Highlights

The company's consolidated revenue for Q2 rose to ₹4,291.91 million, marking a 22.7% increase from ₹3,497.89 million in the same quarter last year. The consolidated net profit for Q2 increased to ₹528.90 million, up 13.3% from ₹466.98 million in the corresponding period of the previous year.

For the half-year ended September 30, 2025, Metropolis Healthcare reported consolidated revenue of ₹8,152.55 million, compared to ₹6,631.44 million in the prior year. The consolidated profit for this six-month period stood at ₹981.38 million, against ₹848.08 million in the previous year.

Interim Dividend Declaration

The Board of Directors of Metropolis Healthcare has declared an interim dividend of ₹4 per equity share of face value ₹2 each for the financial year 2025-26. The record date for the purpose of this interim dividend payment has been set as November 11, 2025.

Business Acquisitions

Metropolis Healthcare has completed several strategic acquisitions during the period:

1. DAPIC Metropolis Healthcare Private Limited in May 2025 for a purchase consideration of ₹346.1 million.
2. Scientific Metropolis Pathology Private Limited in June 2025 for ₹720 million.
3. Dr. R.S. Patil's Ambika Pathology Laboratory in September 2025 for ₹170 million.

Operational Performance

The significant growth in both revenue and profitability underscores Metropolis Healthcare's strong operational performance and market position in the diagnostic services sector. The company's ability to increase its top line by nearly 23% while improving its bottom line by 13.3% demonstrates effective cost management and operational efficiency.

Looking Ahead

As Metropolis Healthcare continues to demonstrate strong financial performance and strategic acquisitions, the company's ability to capitalize on the growing demand for diagnostic services while managing costs effectively and integrating new acquisitions will be crucial for its future success.

Metropolis Healthcare's Q2 results reflect a company on a solid growth path, with improvements across key financial metrics. The declaration of an interim dividend further underscores the company's financial health and its commitment to delivering value to shareholders.